See Bull Run's current pages for Metropolis Healthcare and Dr Lal PathLabs. For sector methodology, see Bull Run's How to Analyse Diagnostic Company Stocks in India.

Q1 FY27 financial scorecard

Dr Lal has the larger patient engine

Dr Lal therefore serves more than twice as many patients.

This is the result of decades of network density, particularly across North India.

The network difference is substantial

At March 31, 2026, Dr Lal reported:

• 312 clinical laboratories;
• 7,727 Patient Service Centres;
• 13,935 pick-up points;
• national and regional reference laboratories.

Metropolis reported a network of roughly:

• 209 laboratories;
• 5,000-plus service or collection centres;
• presence across more than 750 towns.

The definitions are different, but Dr Lal clearly has the larger physical collection and processing network.

Diagnostics is fundamentally a density business

A successful laboratory network needs more than many storefronts.

The economics depend on:

• samples per collection centre;
• samples per laboratory;
• logistics routing;
• machine utilisation;
• pathologist productivity;
• turnaround time;
• digital reporting;
• high-value test mix.

A poorly utilised centre adds cost without creating meaningful operating leverage.

Metropolis is explicitly shifting from network expansion to network productivity

The company spent the prior 12–18 months expanding aggressively.

Management is now focused on increasing the ratio of feeder centres to laboratories and improving throughput from infrastructure already built.

This is important because diagnostics has strong operating leverage once the network exists.

Metropolis still added around 300 service centres during Q1

The company simultaneously rationalised less productive locations.

Management expects continued net network expansion during FY27 while pushing more volume through existing laboratories.

The objective is not simply a larger map.

It is greater revenue from each node.

Patient growth was volume-led at Metropolis

Patient volume increased approximately 10%.

Test volume increased approximately 11%.

Revenue increased 17%.

The company said it had not taken a broad price increase for around 18 months.

This makes the growth quality important.

Metropolis revenue per patient increased 6%

Revenue per patient reached approximately ₹1,219.

Revenue per test reached approximately ₹575.

The company attributes the improvement largely to richer test mix and specialty contribution.

Dr Lal revenue per patient increased even faster

Dr Lal reported revenue per patient of approximately ₹968.

That increased around 10% year on year.

The improvement reflected:

• test mix;
• geographic mix;
• higher tests per patient;
• CGHS/ECHS realization changes.

Why is Metropolis revenue per patient higher despite lower margins?

Revenue per patient measures only the top line.

It does not show the cost required to generate that revenue.

Margins also depend on:

• collection-centre commissions;
• lab utilisation;
• employee cost;
• acquisition integration;
• logistics;
• test reagent cost;
• corporate and B2B pricing.

A higher revenue-per-patient number therefore does not automatically mean a more profitable model.

Metropolis has a major specialty-mix advantage

This is one of the company's most distinctive assets.

Specialty testing includes areas such as:

• genomics;
• oncology diagnostics;
• molecular testing;
• histopathology;
• advanced immunology;
• specialised genetic panels.

These tests often require more expertise and have less direct price competition than routine blood tests.

Genomics is a particularly important Metropolis growth area

The company has invested in specialised genomic capabilities and CAP-accredited infrastructure.

Management describes genomics as one of the fastest-growing components of specialty diagnostics.

This can improve revenue mix without needing routine-test price inflation.

Metropolis added dozens of new specialty tests during Q1

Its broader menu includes thousands of tests and profiles.

A larger specialty menu helps the company deepen relationships with:

• specialist doctors;
• hospitals;
• oncologists;
• genetic counsellors;
• institutional customers.

Dr Lal also competes aggressively in high-end diagnostics

Its scale is not based only on routine pathology.

Dr Lal has invested in:

• genetics;
• molecular diagnostics;
• histopathology;
• cancer diagnostics;
• whole-exome sequencing;
• specialised reference testing.

The company has materially improved turnaround times for advanced sequencing.

Dr Lal's key difference is monetizing premium diagnostics at larger scale

Dr Lal combines advanced tests with a very large routine network.

Routine volumes help absorb:

• reference-lab fixed costs;
• IT investment;
• logistics;
• specialist pathologist expense;
• central corporate costs.

This is one reason the EBITDA margin can remain above 30%.

Dr Lal EBITDA margin reached 31%

That was up from approximately 28.7% a year earlier.

EBITDA increased around 29% while revenue increased 19%.

This is clear operating leverage.

Metropolis also produced strong operating leverage

Metropolis EBITDA increased approximately 27% to about ₹113 crore.

Margin expanded around 210 basis points to 25.2%.

PAT increased approximately 26% to ₹57 crore.

So Metropolis is also improving earnings faster than revenue.

The difference is the starting margin

Dr Lal begins from a structurally stronger current profit base.

Metropolis needs further network productivity and acquisition integration to close the gap.

Management wants Metropolis margins to rise further

The medium-term ambition is toward the high-20s EBITDA-margin range.

Drivers include:

• better service-centre productivity;
• higher specialty mix;
• TruHealth growth;
• Core Diagnostics integration;
• greater lab utilisation;
• digital efficiencies.

TruHealth adds preventive diagnostics exposure

TruHealth generated approximately ₹81 crore Q1 revenue.

It represented around 18% of Metropolis revenue.

Revenue grew approximately 22%.

Preventive packages are attractive because customers may purchase tests without an acute illness.

Preventive testing can create recurring consumer relationships

Traditional pathology is often doctor-prescribed.

Preventive health packages can be marketed more directly to consumers.

This makes branding and digital acquisition more important.

Metropolis B2C revenue reached ₹257 crore

B2C represented approximately 57% of revenue.

It grew around 18%.

B2B generated approximately ₹193 crore and grew around 15%.

That mix gives Metropolis a reasonably balanced channel profile.

Why B2C mix matters

Direct consumer revenue can offer better realization than highly negotiated institutional contracts.

But B2C also requires:

• brand spending;
• collection-centre investment;
• digital marketing;
• home-collection logistics.

A higher B2C share is useful only if customer-acquisition economics remain attractive.

Dr Lal's network historically has powerful consumer brand pull

Its scale in Delhi NCR and North India creates strong customer familiarity.

A dense network can reduce home-collection travel distance and improve turnaround time.

This becomes a self-reinforcing moat in diagnostics.

Test-volume comparison requires a major warning

Metropolis reported approximately 7.83 million Q1 tests.

Dr Lal reported approximately 25.9 million samples/tests under its disclosed operating data.

But diagnostic chains do not always define one "test" the same way.

Metropolis explicitly counts a profile as one test

A wellness profile may contain multiple analytes.

Another company may count individual tests, samples or parameters differently.

That means a three-times-larger raw test count does not necessarily mean three-times more diagnostic work.

Patients are the cleaner volume metric

Patient counts are not perfect either.

But they are generally less sensitive to profile-counting methodology.

On patients:

• Dr Lal: approximately 8.2 million;
• Metropolis: approximately 3.69 million.

Dr Lal therefore clearly has the larger customer base.

Revenue per patient is the useful counterbalance

Metropolis generates approximately ₹1,219 per reported patient.

Dr Lal generates approximately ₹968.

This suggests Metropolis currently serves a richer average test basket or patient mix.

The economics still favour Dr Lal because it converts revenue into profit much more efficiently.

Network scale versus network productivity

Dr Lal's 312 laboratories also exceed Metropolis's current lab count

Metropolis reported approximately 209 laboratories in its Q1 presentation.

Dr Lal reported 312 clinical laboratories at FY26 year-end.

More laboratories can improve geographic turnaround time.

But too many low-volume labs can reduce utilisation.

Metropolis is therefore intentionally increasing centre-to-lab density

Its strategy is to feed more collection points into each laboratory.

This increases machine utilisation and spreads fixed lab expenses across more tests.

It is a straightforward route to margin expansion if volume continues growing.

Dr Lal is expanding from a much denser existing base

Management plans additional labs and selective radiology centres during FY27.

The company is also looking at acquisitions in underrepresented geographies.

This is particularly relevant in South and West India, where Dr Lal's historical dominance is weaker than in North India.

Metropolis has already used acquisitions to accelerate North India expansion

Recent transactions have expanded its presence in markets including:

• Delhi NCR;
• Dehradun;
• Agra;
• specialty diagnostics.

Acquisitions can create geographic scale faster than organic network building.

They also create integration risk

A diagnostic roll-up must harmonize:

• test menus;
• IT systems;
• quality protocols;
• branding;
• pricing;
• lab workflows;
• collection logistics.

Poor integration can destroy the very margin expansion the acquisition was meant to create.

Dr Lal currently has the stronger balance-sheet flexibility

Dr Lal can fund expansion without stressing the balance sheet

Cash can be used for:

• new laboratories;
• acquisitions;
• radiology expansion;
• technology;
• specialty testing;
• shareholder distributions.

The main risk is overpaying for inorganic growth.

Capital efficiency strongly favours Dr Lal

The ROCE gap is unusually large

Dr Lal's approximately 27.6% ROCE is around eleven percentage points above Metropolis.

This tells investors that Dr Lal currently extracts substantially more operating profit from its invested capital base.

Metropolis needs its expansion to raise—not merely grow—ROCE

Adding centres and acquisitions is easy to announce.

The harder goal is increasing:

• patients per centre;
• tests per lab;
• specialty revenue per patient;
• EBITDA per rupee of capital.

If these improve, today's network investment can create strong future returns.

Valuation is closer than the market-cap gap suggests

Dr Lal is worth about 2.4 times Metropolis—but earns about three times the Q1 PAT

Market capitalisation:

• Dr Lal: approximately ₹28,909 crore;
• Metropolis: approximately ₹11,858 crore.

Q1 PAT:

• Dr Lal: ₹170 crore;
• Metropolis: approximately ₹57 crore.

This is why Dr Lal can have a higher market cap while still trading at the lower trailing earnings multiple.

Metropolis is cheaper on book value

Price-to-book is approximately 7.84x.

Dr Lal trades around 11.53x.

The higher Dr Lal multiple is supported by much higher ROE.

Investors are paying more per rupee of book equity because that equity currently earns more.

The price-history fields need corporate-action adjustment

As a result, naïve comparisons of pre-bonus and post-bonus share prices can produce absurd-looking one-year returns and 52-week-high gaps.

Bull Run therefore does not use the current unadjusted one-year-return or historical 52-week-high fields to decide this comparison.

This is exactly why corporate actions matter in quantitative screens

A bonus issue does not destroy shareholder wealth.

It increases the number of shares while reducing price per share mechanically.

A database that compares today's post-bonus price with an old pre-bonus price without adjustment can show a false crash.

Valuation and market capitalisation are far more useful here.

What must Metropolis prove?

• Patient growth should remain double digit.
• Centre productivity must improve as the network expands.
• Specialty revenue should continue increasing its contribution.
• Core Diagnostics and other acquisitions need smooth integration.
• EBITDA margin should progress toward the high-20s.
• ROCE must rise from the mid-teens.
• B2C growth should remain strong without excessive marketing cost.
• Higher revenue per patient must continue converting into PAT.

What must Dr Lal PathLabs prove?

• 19% revenue growth should not depend excessively on one-off realization benefits.
• Patient volumes should remain healthy after recent price/mix gains.
• 31% Q1 EBITDA margin needs reasonable durability.
• Expansion outside North India must generate attractive returns.
• Acquisitions should not dilute ROCE.
• Specialty and genomic investments need continued scale.
• Large cash reserves should be allocated productively.

What could make Metropolis outperform Dr Lal?

Metropolis has more margin and ROCE headroom.

If service-centre density raises lab utilisation while specialty and TruHealth remain fast-growing, the company can expand EBITDA faster than revenue for several years.

Its smaller market capitalisation means each successful acquisition or new region can have a larger percentage impact.

What could make Dr Lal outperform Metropolis?

Dr Lal does not need a major turnaround.

It can continue compounding a network that already produces:

• 31% EBITDA margins;
• 27%-plus ROCE;
• strong cash generation;
• 8-million-plus quarterly patient scale.

If those economics remain durable, the lower current P/E makes the earnings hurdle surprisingly reasonable relative to Metropolis.

Which has the larger diagnostics network?

Dr Lal PathLabs under current disclosed counts.

It reported 312 laboratories and 7,727 patient service centres at FY26 year-end, versus Metropolis at roughly 209 laboratories and more than 5,000 service/collection centres.

Which treats more patients?

Dr Lal PathLabs.

Approximately 8.2 million Q1 patients versus Metropolis at 3.69 million.

Which has higher revenue per patient?

Metropolis Healthcare.

Approximately ₹1,219 versus Dr Lal at ₹968.

The figures reflect different patient and test mixes.

Which has higher EBITDA margins?

Dr Lal PathLabs.

Approximately 31.0% versus Metropolis at 25.2%.

Which has stronger specialty exposure?

Metropolis provides the clearer disclosed specialty-mix KPI.

Specialty diagnostics contributed approximately 40% of its Q1 revenue.

Dr Lal also has significant high-end diagnostics capabilities but does not present the Q1 business under an identical specialty-revenue definition.

Which has higher ROCE?

Dr Lal PathLabs by a wide margin.

Bull Run standardized ROCE is approximately 27.6% versus Metropolis at 16.8%.

Which stock is cheaper?

Dr Lal on trailing earnings; Metropolis on book value.

Dr Lal trades around 53.3x P/E versus Metropolis around 58.8x.

Metropolis trades around 7.84x book versus Dr Lal around 11.53x.

Which is better: Metropolis Healthcare or Dr Lal PathLabs?

Dr Lal PathLabs currently has the stronger valuation-adjusted financial profile. It has much greater patient and network scale, generates more than twice Metropolis's EBITDA, earns a 31% EBITDA margin, produces roughly three times the PAT, carries a large cash balance and earns substantially higher ROCE while trading at a lower P/E.

Metropolis Healthcare has the more visible specialty-mix and network-productivity upside. Specialty diagnostics already contributes around 40% of revenue, TruHealth is growing above 20%, patient and test volumes are rising double digits and management still has meaningful margin-expansion targets.

The deciding factor is execution.

Dr Lal already monetizes diagnostics scale extremely efficiently.

Metropolis is trying to convert a recently expanded and acquired network into that same level of financial productivity.

At September 2026 valuations, Dr Lal PathLabs offers the stronger current combination of growth, margins, cash generation, ROCE and P/E. Metropolis becomes more compelling if specialty mix and centre productivity lift EBITDA margins toward 27–28% and narrow the current return-on-capital gap.

Frequently asked questions